Latest News for: tumor necrosis factor-alpha

Edit

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)

Knoxville Daily Sun 18 Dec 2024
ZYMFENTRA blocks the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be overproduced in response to certain diseases and cause the immune system to attack normal, healthy parts of the body.
Edit

Ignite Biomedical Achieves Key Milestone in Precision Medicine with Successful Analytical Validation of TNF-alpha Inhibitor ...

ACCESSWIRE 10 Dec 2024
("Ignite"), a leader in AI-driven biomarker innovation for precision medicine, today announced the successful completion of analytical validation for its Tumor Necrosis Factor-alpha Inhibitor (TNFi) Treatment Response Predictor (TRP).
Edit

TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies

Pharmiweb 05 Dec 2024
TILT-123, an oncolytic adenovirus armed with tumor necrosis factor alpha (TNFα) and interleukin-2 (IL-2), is designed to enhance the efficacy of T-cell therapies, including immune checkpoint blockade or adoptive cell transfer.
Edit

Rheumatoid Arthritis Market Expected to Experience Major Growth by 2034, According to DelveInsight | AbbVie, ...

GetNews 29 Nov 2024
... designed to validate the use of intravenous (IV) Lymphoseek (Tc 99m tilmanocept) imaging in predicting clinical responses in RA patients starting anti-tumor necrosis factor alpha (TNFα) therapy.
Edit

Axial Spondyloarthritis Therapeutics Market Size was ~USD 9 Million in 2023, estimated DelveInsight

GetNews 21 Nov 2024
Download the report to understand which factors are driving Axial Spondyloarthritis epidemiology trends @ ... SIMPONI is a human IgG1? monoclonal antibody specific for human tumor necrosis factor-alpha (TNF–-a) that exhibits multiple glycoforms ... 1.
Edit

CBD shows promise in managing fever and inflammation

PsyPost 13 Nov 2024
This sampling allowed them to measure various chemicals in the blood and tissue that contribute to fever and inflammation, including tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and prostaglandin E2.
Edit

Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

GetNews 28 Oct 2024
... signature of a patient's tumor ... TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines.
Edit

Oncolytic Adenovirus Market Targets USD 250 Billion Valuation by 2033 at a 7.5% of CAGR

Pharmiweb 21 Oct 2024
TILT Biotherapeutic’s head of R&D Riikka Havunen was awarded oral presentation “Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors ...
Edit

Melanoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, Companies ...

GetNews 17 Oct 2024
... in patients with resectable tumors ... TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines.
Edit

Curcumin and Kidney Health: Benefits, Risks, and Who Should Avoid It

The Epoch Times 11 Oct 2024
It is commonly used to prevent various chronic diseases ... A 2023 study found that curcumin can inhibit several key inflammatory factors, such as interleukin-6, and tumor necrosis factor-alpha ... ....
Edit

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral ...

ACCESSWIRE 30 Sep 2024
On September 16, 2024, Tharimmune announced it entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor alpha monoclonal antibody, infliximab.
Edit

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Pharmiweb 30 Sep 2024
On September 16, 2024, Tharimmune announced it entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor alpha monoclonal antibody, infliximab.
Edit

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

ACCESSWIRE 16 Sep 2024
... an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab ... Tumor necrosis factor-alpha is a signaling protein involved in acute phase reactions and systemic inflammation.
Edit

What Does the Science Say About Alcohol Consumption?

GlobalResearch 15 Sep 2024
* ... 1 ... 2 ... 2 ... The metabolism of alcohol in your liver also triggers a proinflammatory response, releasing cytokines such as IL-6 and tumor necrosis factor alpha ... Estrogens are one of the primary factors contributing to increasing your cancer risk ... * ... Notes.
Edit

TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024

Pharmiweb 09 Sep 2024
TILT-123, an oncolytic adenovirus armed with tumor necrosis factor alpha (TNFα) and interleukin-2 (IL-2), is designed to enhance the efficacy of T-cell therapies, including immune checkpoint blockade or adoptive cell transfer ... TNF alpha and IL-2.

Most Viewed

×